6620 漢達 - 各位同學會關注漢達的朋友們，大家好。剛剛收到朋友傳的一則...

阿和 · 2025-08-12T07:47:56Z

各位同學會關注漢達的朋友們，大家好。剛剛收到朋友傳的一則資訊給我，原文如下，想請問各位高手，這是以利多解讀？還是其他方面解讀呢？請各位提供高見，非常感謝。由於阿和的英文不好，所以請各位用翻譯軟體自行翻譯會比較準一點。 Xspray Pharma signs license agreement with Handa Therapeutics – to receive up to double-digit royalty on Handa’s net proceeds Xspray Pharma (“Xspray”) has entered into a license agreement with Handa Therapeutics (“Handa”) granting Handa a non-exclusive license to certain Xspray patents. The license covers commercialization of a dasatinib product in the US market and, at a later stage, selected Asian markets. Under the agreement, Xspray will receive up to a double-digit royalty on Handa’s net proceeds. This is the first out-licensing from Xspray’s broad patent portfolio and marks an important milestone in capitalizing on its intellectual property assets. The company’s core strategy to develop and commercialize improved PKI-drugs using its patented HyNap technology remains unchanged. Its lead product candidate Dasynoc awaits FDA-approval with a PDUFA date of October 7, 2025. However, further licensing agreements may be considered on a case-by-case basis. “The agreement confirms the value of our patent portfolio and demonstrates that our long-term work to build our comprehensive patent portfolio is paying off. As for the dasatinib market, I’m convinced that when Dasynoc is launched it will be seen as the premium product in its market segment as it combines pH-independent absorption with lower dose strength and high precision, eliminating sensitivity to all acid-reducing agents.” says Per Andersson, CEO of Xspray Pharma. The agreement further ensures that Xspray’s planned launch of Dasynoc can proceed without being affected by any United States regulatory exclusivities that may be associated with Handa’s product. Handa’s dasatinib product has not yet been launched. For further information, please contact: Jacob Nyberg, IR Xspray Pharma AB (publ) Tel: + 46 (0) 70 767 08 83 E-mail: ir@xspray.com